This company is no longer active
FZRQ Stock Overview
Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Immune Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0031 |
52 Week High | US$0 |
52 Week Low | US$0 |
Beta | 0 |
1 Month Change | 1,450.00% |
3 Month Change | 210.00% |
1 Year Change | 3.33% |
3 Year Change | -99.88% |
5 Year Change | -99.99% |
Change since IPO | n/a |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
FZRQ | DE Biotechs | DE Market | |
---|---|---|---|
7D | -68.7% | 2.3% | 1.2% |
1Y | 3.3% | 31.8% | 5.5% |
Return vs Industry: FZRQ exceeded the German Biotechs industry which returned -10.6% over the past year.
Return vs Market: FZRQ exceeded the German Market which returned -20.4% over the past year.
Price Volatility
FZRQ volatility | |
---|---|
FZRQ Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: FZRQ's share price has been volatile over the past 3 months.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | n/a | Gary Rabin | https://www.immunepharma.com |
Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company’s lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis.
Immune Pharmaceuticals, Inc. Fundamentals Summary
FZRQ fundamental statistics | |
---|---|
Market cap | €369.55k |
Earnings (TTM) | -€31.61m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs FZRQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FZRQ income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$34.39m |
Earnings | -US$34.39m |
Last Reported Earnings
Sep 30, 2018
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did FZRQ perform over the long term?
See historical performance and comparison